Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Citius Oncology, Inc.NASDAQ: CTOR
Retained Earnings · Q2 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q2 FY2026 retained earnings was -$96.18M, compared with -$53.67M a year earlier.
Context
- Retained earnings amounted to 95.5% of total assets at the end of Q2 FY2026, up 36.8 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -79.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (64.04M) USD
- Year-over-year change
- -63.0%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (64.04M) | -63.0% |
| FY2024 | 2024-09-30 | (39.28M) | -116.7% |
| FY2023 | 2023-09-30 | (18.13M) | -233.7% |
| FY2022 | 2022-09-30 | (5.43M) | — |
Retained Earnings vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 retained earnings of -$96.18M is the highest of the 10 companies compared; the peer median is -$458.27M.
- Its year-over-year change of -79.2% is the 9th highest of 10, against a peer median of -15.5%.
- Retained earnings amounts to 95.5% of total assets for CTOR, versus a peer median of 365.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CTORCitius Oncology, Inc. | Mar 2026 | -$96.18M | -79.2% | — | 95.5% |
| Mar 2026 | -$141.24M | +17.2% | — | 213.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | -$160.23M | -15.5% | — | 1798.1% |
| Mar 2026 | -$245.51M | -44.7% | — | 365.2% | |
| Mar 2026 | -$311.21M | -17.4% | — | 358.7% | |
| Mar 2026 | -$458.27M | +3.2% | — | 776.5% | |
| Mar 2026 | -$965.06M | -63.8% | — | 328.7% | |
| Mar 2026 | -$992.32M | -5.0% | — | 843.7% | |
| Mar 2026 | -$1.37B | -180.4% | — | 270.9% | |
| Mar 2026 | -$1.57B | -9.0% | — | 549.5% | |
| Peer median (excluding CTOR) | -$458.27M | -15.5% | — | 365.2% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.